Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Thursday, Benzinga reports. JMP Securities currently has a $5.00 price target on the stock.

TSHA has been the subject of several other research reports. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday. Chardan Capital reaffirmed a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, June 18th. Piper Sandler initiated coverage on shares of Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price on the stock. Jefferies Financial Group reaffirmed a buy rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Finally, Canaccord Genuity Group reaffirmed a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $7.00.

Taysha Gene Therapies Trading Up 7.2 %

Shares of TSHA stock opened at $2.96 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The firm has a market cap of $553.57 million, a PE ratio of -6.04 and a beta of 0.50. The company has a 50-day moving average of $2.99 and a two-hundred day moving average of $2.39. Taysha Gene Therapies has a 1-year low of $0.50 and a 1-year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter last year, the firm posted ($0.28) earnings per share. On average, analysts predict that Taysha Gene Therapies will post -0.43 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter worth about $370,000. Citigroup Inc. purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $888,000. FMR LLC grew its holdings in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after purchasing an additional 23,378,974 shares during the period. EAM Investors LLC purchased a new position in Taysha Gene Therapies in the 3rd quarter worth approximately $1,060,000. Finally, Acuta Capital Partners LLC purchased a new position in Taysha Gene Therapies in the 3rd quarter worth approximately $12,096,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.